GlobeNewswire: CanaQuest Medical Corp Contains the last 10 of 21 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:27:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/03/11/2191474/0/en/CANAQUEST-SIGNS-MEDICINAL-CANNABIS-EDUCATION-PARTNERSHIP-WITH-THE-CANADIAN-CANNABIS-DISPUTE-RESOLUTION-CENTRE.html?f=22&fvtc=4&fvtv=41706CANAQUEST SIGNS MEDICINAL CANNABIS EDUCATION PARTNERSHIP WITH THE CANADIAN CANNABIS DISPUTE RESOLUTION CENTRE2021-03-11T14:00:00Z<![CDATA[TORONTO, March 11, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to announce its new partnership with the Canadian Cannabis Dispute Resolution Centre ("CCDRC"), a national organization that has developed cannabis-related education and training programs, both domestically and internationally, to assist different levels of government, the private sector, industry-specific organizations and associations.]]>https://www.globenewswire.com/news-release/2021/02/02/2168285/0/en/CANAQUEST-SIGNS-MENTANINE-AND-MENTABINOL-PRODUCTION-AND-DISTRIBUTION-AGREEMENT-WITH-PURCANN-PHARMA-AND-SILICYCLE-INC.html?f=22&fvtc=4&fvtv=41706CANAQUEST SIGNS MENTANINE® AND MENTABINOL® PRODUCTION AND DISTRIBUTION AGREEMENT WITH PURCANN PHARMA AND SILICYCLE INC.2021-02-02T14:00:00Z<![CDATA[TORONTO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced a new production and distribution agreement with PurCann Pharma (“PurCann“) and SiliCycle Inc. (“SiliCycle“). PurCann, a subsidiary of SiliCycle, is recognized for its unique expertise in the Extraction-Purification and commercialization of cannabinoids.]]>https://www.globenewswire.com/news-release/2021/01/19/2160720/0/en/CANAQUEST-PRESIDENT-INTERVIEWED-BY-THE-WALL-STREET-ANALYZER.html?f=22&fvtc=4&fvtv=41706CANAQUEST PRESIDENT INTERVIEWED BY THE WALL STREET ANALYZER2021-01-19T14:00:00Z<![CDATA[TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to release a recent interview with company Co-founder and President, Paul Ramsay, on The Wall Street Analyzer, a multi-media financial research and publishing company reporting to the investment community on publicly held companies. It can be heard in full at:]]>https://www.globenewswire.com/news-release/2020/12/03/2139208/0/en/CANAQUEST-ANNOUNCES-MENTABINOL-A-SCIENTIFIC-DISCOVERY-AS-PUBLISHED-IN-THE-JOURNAL-OF-NEUROSCIENCE.html?f=22&fvtc=4&fvtv=41706CANAQUEST ANNOUNCES MENTABINOL® A SCIENTIFIC DISCOVERY, AS PUBLISHED IN THE JOURNAL OF NEUROSCIENCE2020-12-03T14:00:00Z<![CDATA[TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that The Journal of Neuroscience has published the findings of Western University’s research leading to the discovery of the Mentabinol®, a patented THC based formulation & L-theanine, a compound derived from Green Tea leaves.]]>MENTABINOL® SCIENTIFIC DISCOVERY AS PUBLISHED IN THE JOURNAL OF NEUROSCIENCECanaQuest Medical Corphttps://www.globenewswire.com/news-release/2020/09/17/2095268/0/en/CANAQUEST-MEDICAL-CORP-SECURES-APPROVAL-FOR-LISTING-ON-THE-OCMX-AN-ONLINE-INVESTOR-AND-FINANCIAL-CONNECTION-PORTAL.html?f=22&fvtc=4&fvtv=41706CANAQUEST MEDICAL CORP SECURES APPROVAL FOR LISTING ON THE OCMX™, AN ONLINE INVESTOR AND FINANCIAL CONNECTION PORTAL2020-09-17T13:00:00Z<![CDATA[TORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that it has been approved to raise capital on The OCMX™, an online portal that publicizes and provides financial connections to public and privately held investment opportunities.]]>https://www.globenewswire.com/news-release/2020/07/14/2062070/0/en/UPDATE-CANAQUEST-MEDICAL-CORP-FILES-PROVISIONAL-PATENT-FOR-MENTANINE-OMEGA-3-PURE-CANNABIDIOL-CBD-FORMULATION-BOOSTING-MENTAL-HEALTH-EFFICACY-WHILE-MINIMIZING-CBD-DOSAGE.html?f=22&fvtc=4&fvtv=41706UPDATE: CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE2020-07-14T15:04:21Z<![CDATA[TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing cannabis/hemp molecules and botanical compounds, has filed a Provisional Cannabidiol/Omega-3 Patent, trade named Mentanine®, which was developed as a result of its sponsored research program at Western University, based in London, Ontario, Canada.]]>MENTANINE - NANO CBD/OMEGA WATER SOLUABLE POWDER FORMULACANAQUEST MEDICAL CORPhttps://www.globenewswire.com/news-release/2020/07/14/2061976/0/en/CANAQUEST-MEDICAL-CORP-FILES-PROVISIONAL-PATENT-FOR-MENTANINE-OMEGA-3-PURE-CANNABIDIOL-CBD-FORMULATION-BOOSTING-MENTAL-HEALTH-EFFICACY-WHILE-MINIMIZING-CBD-DOSAGE.html?f=22&fvtc=4&fvtv=41706CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE2020-07-14T13:00:00Z<![CDATA[TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing cannabis/hemp molecules and botanical compounds, has filed a Provisional Cannabidiol/Omega-3 Patent, trade named Mentanine®, which was developed as a result of its sponsored research program at Western University, based in London, Ontario, Canada.]]>MENTANINE - NANO CBD/OMEGA WATER SOLUABLE POWDER FORMULACANAQUEST MEDICAL CORPhttps://www.globenewswire.com/news-release/2020/02/06/1981118/0/en/Canaquest-Medical-Corp-Awaits-Health-Canada-Approval-for-Sales-and-Export-of-Mentabinol.html?f=22&fvtc=4&fvtv=41706Canaquest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®2020-02-06T14:00:00Z<![CDATA[TORONTO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a developer of novel health products utilizing cannabis, hemp, and botanical extracts, including algae oils, today announced it has applied to Health Canada for approval to produce, sell and export Mentabinol® (THC based, all-natural formulation) under the Cannabis Act.]]>https://www.globenewswire.com/news-release/2019/10/29/1937331/0/en/CANAQUEST-MEDICAL-CORP-is-the-Winner-of-the-Go-Global-Awards-Business-of-the-Year-Category-of-Life-Science-presented-by-the-International-Trade-Council.html?f=22&fvtc=4&fvtv=41706CANAQUEST MEDICAL CORP is the Winner of the Go Global Awards "Business of the Year – Category of Life Science” presented by the International Trade Council2019-10-29T16:19:53Z<![CDATA[Research & development is a primary focus for this medical cannabis company]]>https://www.globenewswire.com/news-release/2019/09/17/1916753/0/en/CANAQUEST-MEDICAL-CORP-announces-filing-of-INTERNATIONAL-CANNABIS-PATENT.html?f=22&fvtc=4&fvtv=41706CANAQUEST MEDICAL CORP announces filing of INTERNATIONAL CANNABIS PATENT2019-09-17T13:00:00Z<![CDATA[A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL (“THC”) FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTS]]>